Loading...
Market
Number of Zantac Lawsuits Settled in Favor of Plaintiffs by 2024
4
Resolution / Starting Odds
0-10 • 25%
11-50 • 25%
51-100 • 25%
More than 100 • 25%
Court records and legal news reports
Story
Chicago Jury Rejects 89-Year-Old's $640 Million Claim That Zantac Caused Cancer in First Trial
May 23, 2024, 05:10 PM
A jury in Chicago has rejected an Illinois woman's claim that the now-discontinued heartburn drug Zantac caused her colon cancer. The trial, which involved GlaxoSmithKline and Boehringer Ingelheim, was the first of thousands of lawsuits making similar allegations. The plaintiff, an 89-year-old woman from Brookfield, alleged that Zantac caused her colon cancer and sought $640 million in damages. The jury, composed of nine women and three men, deliberated over the case. Lawyers for the pharmaceutical companies argued that no credible evidence linked Zantac to cancer, and the jury ultimately sided with the defense. The woman also claimed debilitating symptoms as part of her case.
View original story
Similar markets
Less than 10,000 • 33%
10,000 - 50,000 • 34%
More than 50,000 • 33%
GSK wins • 33%
GSK loses • 33%
Settlement reached • 33%
Less than $1 billion • 33%
$1 billion to $5 billion • 33%
More than $5 billion • 33%
No other major lawsuits • 25%
Minor settlements • 25%
Major settlements similar to Zantac • 25%
Litigations lead to trials • 25%
0-10 • 25%
11-20 • 25%
21-30 • 25%
31+ • 25%
None • 25%
1-10 • 25%
11-20 • 25%
More than 20 • 25%
No new settlements • 25%
1-5 new settlements • 25%
6-10 new settlements • 25%
More than 10 new settlements • 25%
1-2 lawsuits • 25%
3-5 lawsuits • 25%
More than 5 lawsuits • 25%
No additional lawsuits • 25%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
Below $1 billion • 33%
$1 billion - $5 billion • 33%
Above $5 billion • 34%